Accera, Inc. to Support the Alzheimer’s Foundation of America’s (AFA) National Memory Screening Day (NMSD)
BROOMFIELD, Colo., Sept. 26, 2012 /PRNewswire/ — Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today that it is a silver sponsor of the Alzheimer’s Foundation of America’s (AFA) National Memory Screening Day (NMSD) on November 13, 2012 during National Alzheimer’s Disease Awareness Month.
“We’re pleased to continue our relationship with the Alzheimer’s Foundation,” said Holger Kunze, president and CEO of Accera. “Our company strongly advocates for doing everything possible that can benefit Alzheimer’s patients and their caregivers and find the Alzheimer’s Foundation’s position on comprehensive care to be in direct alliance with our approach.”
Accera has developed and sells Axona(®), a specially formulated, prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate AD. It is the first proprietary commercialized AD therapy that addresses the well-recognized physiological hallmark of the brain’s inability to optimally metabolize glucose (hypometabolism) by providing an alternative energy source for brain cells.
Eric J. Hall, AFA’s president and CEO, stated, “The Alzheimer’s Foundation of America is delighted to have the continued support of Accera as a sponsor of National Memory Screening Day. Its support underscores the company’s recognition of the importance of proper diagnosis and its desire to help us fulfill our mission of improving quality of life for people with Alzheimer’s disease and their families.” NMSD, an annual initiative initiated by AFA in 2003, provides free, confidential memory screenings to individuals concerned about memory loss or who want to check their memory now and for future comparison with the objective of early detection and intervention. Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation. The screening results do not represent a diagnosis, but can indicate whether someone with below-normal results or with concerns should follow up with a physician. To find a screening site, visit www.nationalmemoryscreening.org.
About Accera, Inc.
Accera, Inc. is a privately held commercial-stage healthcare company that developed and now markets Axona in the US. Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases. For more information about Accera, please visit www.accerapharma.com.
)Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease. For more information about Axona, please visit www.about-axona.com or ask your physician.
Accera, Inc. Tiberend Strategic Advisors, Inc. (303) 999-3705 (212) 827-0020 Bill Poncy Andrew Mielach VP Commercial Development firstname.lastname@example.org email@example.com
SOURCE Accera, Inc.